Parotoid gland secretions of the Egyptian toad (Bufo relgularis): In vivo antitumor effect on Ehrlich ascites carcinoma bearing mice
El-Naggar, S., Basyony, M., El-Feki, S., Kandyel, R. (2023). Parotoid gland secretions of the Egyptian toad (Bufo relgularis): In vivo antitumor effect on Ehrlich ascites carcinoma bearing mice. EKB Journal Management System, 9(1), 33-45. doi: 10.21608/jbaar.2023.284928
Sabry Ali El-Naggar; Mohamed Aboulfotouh Basyony; Seham Mohamed El-Feki; Ramadan Mahmoud Kandyel. "Parotoid gland secretions of the Egyptian toad (Bufo relgularis): In vivo antitumor effect on Ehrlich ascites carcinoma bearing mice". EKB Journal Management System, 9, 1, 2023, 33-45. doi: 10.21608/jbaar.2023.284928
El-Naggar, S., Basyony, M., El-Feki, S., Kandyel, R. (2023). 'Parotoid gland secretions of the Egyptian toad (Bufo relgularis): In vivo antitumor effect on Ehrlich ascites carcinoma bearing mice', EKB Journal Management System, 9(1), pp. 33-45. doi: 10.21608/jbaar.2023.284928
El-Naggar, S., Basyony, M., El-Feki, S., Kandyel, R. Parotoid gland secretions of the Egyptian toad (Bufo relgularis): In vivo antitumor effect on Ehrlich ascites carcinoma bearing mice. EKB Journal Management System, 2023; 9(1): 33-45. doi: 10.21608/jbaar.2023.284928

Parotoid gland secretions of the Egyptian toad (Bufo relgularis): In vivo antitumor effect on Ehrlich ascites carcinoma bearing mice

Journal of Bioscience and Applied Research
Volume 9, Issue 1, March 2023, Page 33-45  XML PDF (804.01 K)
Document Type: Original Article
DOI: 10.21608/jbaar.2023.284928
View on SCiNiTO View on SCiNiTO
Authors
Sabry Ali El-Naggar email ; Mohamed Aboulfotouh Basyony; Seham Mohamed El-Feki* ; Ramadan Mahmoud Kandyel
Zoology Department, Faculty of Science, Tanta University, Egypt
Abstract
Background: Parotoid gland secretions (PGS) contain several bioactive compounds with potential applications for drug development. Objective: This study was conducted to evaluate the in vivo antitumor effect of PGS collected from the Egyptian toad, Bufo relgularis using Ehrlich ascites carcinoma-bearing mice (EAC). Methods: The median lethal dose (LD50) of PGS was determined, then forty CD-1 female mice were divided into 4 groups (n=10) as follows: Group (Gp1) served as a negative control. Gp2-Gp4 had inoculated intraperitoneally (i.p) with 1×106 EAC cells/mouse. Then, Gp2 was left as a positive control (EAC- bearing mice). After 24 hours, Gp3 had injected i.p with Cisplatin (Cis) (2 mg/kg) on day 1 for 7 consecutive days. Gp4 had injected with 1/10 LD50 of PGS (7.85 mg/kg, b.wt) i.p for 7 consecutive days. All groups were sacrificed on day 14 to collect blood samples. The percentages of total body weight (% bwt) change, tumor volume, and total tumor cell counts were determined. Alanine and aspartate transaminases (ALT and AST), antioxidant /oxidant biomarkers (SOD, CAT, and MDA), and histological investigations of liver tissues were evaluated. Results: The results showed that the % b.wt changes were increased in EAC- bearing mice, while the treatment of EAC- bearing mice with PGS decreased its % b.wt changes. The treatment of EAC- bearing mice with PGS decreased the tumor volume and its counts. PGS treatment led to an improvement in AST, ALT, and antioxidant enzyme activities, and ameliorated the histopathological changes in the liver induced by EAC inoculation. Conclusion: We concluded that PGS had a potential anticancer effect against EAC- bearing mice.
Keywords
Parotoid gland; Secretions; EAC- bearing mice; Pathophysiological
Statistics
Article View: 255
PDF Download: 332